Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG 20 vs placebo in advanced hepatocellular carcinoma after prior systemic therapy
CTR20130259Phase 3Active
- Sponsor
- Polaris Group
- Start
- Nov 2013
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of Pegargiminase in hepatocellular carcinoma (HCC), sponsored by Polaris Group. Started Nov 2013; status: active.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20130259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20130259.